Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide and Pyruvate for Open Angle Glaucoma
NCT05695027Phase 3Active, not recruiting
- Sponsor
- Columbia University
- Start
- Mar 2023
- Primary completion
- Aug 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nicotinamide, Pyruvic acid in primary open-angle glaucoma (POAG), Pseudoexfoliation Glaucoma (PEG), pigmentary glaucoma (PG), sponsored by Columbia University. Started Mar 2023; status: active, not recruiting.
02
Drugs
nicotinamidePyruvic acid
03
Conditions
primary open-angle glaucoma (POAG)Pseudoexfoliation Glaucoma (PEG)pigmentary glaucoma (PG)
Beyond the preview
Go deeper on NCT05695027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695027.